BRIEF—Transpire Bio inks second deal with Recipharm

Transpire Bio, a USA-based developer of inhaled therapeutics for pulmonary and systemic diseases, today announced a second agreement with Sweden’s Recipharm to develop TRB-3 and TRB-4, inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease.

TRB-3 and TRB-4, marking the rapid progression of the Transpire pipeline, are inhaled products being developed for advanced markets. With a focus on streamlining the development process, these two new products will expand Transpire's reach as it looks to bring new, complex inhaled medicines to market.

Earlier this year, Transpire entered into an agreement with Recipharm for the development and commercialization of TRB-1 and TRB-2.